Dear Loyal Reader, | Plain and simple, small-cap stocks are where the real money will be made in 2021. That's why Ian King has released three new "1,000% in one year" recommendations to subscribers of his small-cap stock research advisory, New Era Fortunes… The first is a $1 microcap that he says could double in three months. The second is what Ian calls an "instant unicorn" opportunity — a tiny company that reaches a $1 billion valuation, virtually overnight. And the third is a small immunotherapy company with a COVID-19 treatment that the Food and Drug Administration (FDA) just approved for emergency use. The stock soared nearly 30% in January … and 18% since the middle of last week. With FDA approval this firm's technology could disrupt a $60 billion industry. To get the scoop on these recommendations, you have to be a subscriber of New Era Fortunes. Subscribers have already seen top gains as high as 108% in three months, 248% in nine months and 587% in seven months on open positions. Today, you have the opportunity to join them for the lowest price Ian's ever offered. But you're about to miss your chance. That's because this special offer closes tomorrow at midnight EST. Simply click here for full details… Regards, Steve Fernandez Research Analyst, Banyan Hill Publishing (c) 2021 Banyan Hill Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 888-898-2227) Legal Notice The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: http://banyanhill.com/contact-us Remove your email from this list: Click here to Unsubscribe |
No comments:
Post a Comment